Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, ...

Those who regularly wear saris and petticoats that are tied around the waist tightly for a long time are prone to skin ...

Esophageal squamous cell carcinoma (ESCC) is a severe health threat, being a predominant subtype of esophageal cancer and ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Shares of Phio Pharmaceuticals Corp. surged 330% Monday afternoon, reaching their highest levels in nearly eight months, to ...

Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell CarcinomaMarlborough, Massachusetts--(Newsfile Corp. - January ...

Oral squamous cell carcinoma (OSCC), a major subset of head and neck cancers, is known for its high mortality rates and limited treatment options.

Phio Pharmaceuticals reports promising Phase 1b trial results for PH-762, showing complete tumor clearance in two patients with no significant adverse effects.

The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.

The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...

Phio Pharmaceuticals shares more than tripled after the company said it saw positive results from its Phase 1b trial for its cancer treatment PH-762. Shares were recently up more than 270% to $6.30 in ...

Pharmaceuticals announced positive results from the Phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 ...